Vistagen to Present at Psych Congress 2026
Globe Newswire (Thu, 10-Sep 8:30 AM ET)
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
Globe Newswire (Fri, 14-Aug 8:32 AM ET)
Globe Newswire (Thu, 6-Aug 8:30 AM ET)
Market Chameleon (Tue, 4-Aug 6:36 AM ET)
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
Globe Newswire (Tue, 4-Aug 5:00 AM ET)
Vistagen Appoints Douglas J. Williamson to its Board of Directors
Globe Newswire (Fri, 31-Jul 8:30 AM ET)
Business Wire (Tue, 30-Jun 8:00 AM ET)
Vistagen Advances Three Key Neuro Programs and Strengthens R&D Despite Increased Net Loss
Market Chameleon (Tue, 16-Jun 7:11 AM ET)
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Business Wire (Mon, 15-Jun 4:30 PM ET)
Vistagen Completes Key Phase 3 Trial for Social Anxiety—PALISADE-3 Results to Arrive by Year End
Market Chameleon (Mon, 3-Nov 6:19 AM ET)
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
Vistagen Therapeutics trades on the NASDAQ stock market under the symbol VTGN.
As of September 10, 2026, VTGN stock price was flat at $0.24 with 284,253 million shares trading.
VTGN has a beta of -0.07, meaning it tends to be less sensitive to market movements. VTGN has a correlation of 0.00 to the broad based SPY ETF.
VTGN has a market cap of $10.61 million. This is considered a Sub-Micro Cap stock.
Last quarter Vistagen Therapeutics reported $1 million in Revenue and -$.30 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.05.
In the last 3 years, VTGN traded as high as $6.98 and as low as $.20.
The top ETF exchange traded funds that VTGN belongs to (by Net Assets): VTI, PSIL, VXF.
VTGN has underperformed the market in the last year with a price return of -93.4% while the SPY ETF gained +17.7%. VTGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -55.6% and -8.1%, respectively, while the SPY returned +3.1% and -1.1%, respectively.
VTGN support price is $.22 and resistance is $.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VTGN shares will trade within this expected range on the day.
